NCT Number: NCT07437391
The current study is planned to see the effect of L-carnitine supplementation in preterm neonates suffering from RDS among the local population, as there is no such evidence available for the local population and there are conflicting statistics regarding the discharge rate of these neonates.
Interested in participating?
Request Info1 hour–24 hour
All sexes
Interventional
Not applicable
Muzaffargarh, Punjab Province, 32400, Pakistan
Location status: Recruiting
Athar Razzaq, FCPS
PRINCIPAL_INVESTIGATOR
Athar Razzaq, PCPS
CONTACT
Muhammad Sarfraz, FCPS
CONTACT
Muhammad Sarfraz, FCPS
PRINCIPAL_INVESTIGATOR
Given the contradictory results (discharge rate), additional rigorously designed studies are necessary to elucidate the impact of L-carnitine supplementation on short-term neonatal outcomes, including weight gain, discharge rate, and mortality. The proposed research aims to fill this knowledge gap by systematically evaluating the clinical efficacy and safety of L-carnitine supplementation in L-carnitine-deficient neonates. The findings would provide evidence-based suggestions on whether L-carnitine is a useful, safe, and potentially beneficial adjunct in managing preterm neonates with RDS, particularly in addressing metabolic needs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day, in conjunction with a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Patients will get a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Time frame: 30 days
If a patient will die in the hospital, it will be considered as mortality, otherwise taken as discharged alive.
Time frame: 30 days
Change in weight will be measured at discharge and compared with the baseline measure. An increase in the weight from baseline will be considered effectiveness of the treatment.
Contact information is provided by the study sponsor or research team.
Athar Razzaq, FCPS
CONTACT
Muhammad Sarfraz, FCPS
CONTACT
Muhammad Aamir Latif
Other
Effect of L-Carnitine Supplementation in Preterm Neonates Suffering From Respiratory Distress Syndrome (RDS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06684379
COVID-19, Coronaviridae Infections
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07570121
Apnea, Apnea of Prematurity
Indianapolis, Indiana, United States
View Trial DetailsNCT07579013
Lung Diseases, Respiration Disorders
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT06776783
Lung Diseases, Pre-term Infants
Little Rock, Arkansas, United States
View Trial Details